苯磺酸左旋氨氯地平联合厄贝沙坦治疗原发性 高血压病的疗效观察. (Chinese)

OBJECTIVE: To probe into the clinic efficacy of levamlodipine besylate combined with irbesartan on essential hypertension. METHODS: Totally 94 patients with essential hypertension admitted into Dongguan Zhangmutou Town Community Health Service Center in 2017 were extracted to be divided into the observation group and the control group via the random number table, with 47 cases in each. Patients in the control group were treated with irbesartan, and the observation group received levamlodipine besylate combined with irbesartan. The systolic blood pressure (SBP), diastolic blood pressure (DBP) and adverse drug reactions were observed in two groups before and after treatment. RESULTS: Before treatment, the SBP and DBP levels of patients in both groups were relatively high, and the difference was not statistically significant (P>0.05). After treatment, the SBP and DBP levels of patients in the observation group were significantly lower than those in the control group, and the control rates of SBP and DBP were significantly higher than those in the control group, with statistically significant differences (P<0.05). The incidence of adverse drug reactions in observation group and control group were 6. 38% (3/47) and 8. 51% (4/47), respectively, and the difference was not statistically significant (P>0.05). CONCLUSIONS: Levamlodipine besylate combined with irbesartan can optimize the blood pressure control in patients with essential hypertension without increasing adverse drug reactions. [ABSTRACT FROM AUTHOR]

目的:探讨苯磺酸左旋氨氯地平联合厄贝沙坦治疗原发性高血压病的临床疗效。方法:选取2017 年东莞市樟木头镇社 区卫生服务中心收治的原发性高血压病患者94 例,以随机数字表法分为观察组和对照组,每组47 例。对照组患者给予厄贝沙坦 治疗,观察组患者给予苯磺酸左旋氨氯地平联合厄贝沙坦治疗。观察两组患者治疗前后的收缩压(SBP)、舒张压(DBP)和不良反 应发生情况。结果:治疗前,两组患者SBP、DBP 水平均较高,差异无统计学意义(P>0.05);治疗后,观察组患者SBP、DBP 水平明 显低于对照组,SBP 控制率、DBP 控制率明显高于对照组,差异均有统计学意义(P<0.05)。观察组、对照组患者的不良反应发生 率分别为6. 38%(3/47)、8. 51%(4/47),差异无统计学意义(P>0.05)。结论:苯磺酸左旋氨氯地平联合厄贝沙坦可优化原发性 高血压病患者的血压控制效果,且不会增加不良反应。 [ABSTRACT FROM AUTHOR]

Copyright of Evaluation & Analysis of Drug-Use in Hospitals of China is the property of Evaluation & Analysis of Drug-Use in Hospitals of China Editorial Board and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)